User:Mr. Ibrahem/Canakinumab

Canakinumab, sold under the brand name Ilaris, is a medication used to treat periodic fever syndromes, gout, and Still's disease. The periodic fever syndromes it is used in include cryopyrin-associated periodic syndromes (CAPS), familial mediterranean fever (FMF), tumour necrosis factor receptor associated periodic syndrome (TRAPS), and HIDS/MKD. It is given by injection under the skin.

Common side effects include infections of the nose and throat, abdominal pain, nausea, and injection-site reactions. Other side effects may include infections. Those on the medication should not receive live vaccines. It is a monoclonal antibody that binds to and blocks interleukin-1 beta.

Canakinumab was approved for medical use in the United States and Europe in 2009. In the United Kingdom 150 mg costs the NHS about £9,900 as of 2023. This amount in the United States is about 17,500 USD.